Immuron announces record Travelan® sales globally, Australia and USA
2024年7月15日 - 9:00PM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company, is pleased to
announce record sales (unaudited) of Travelan®, an over-the-counter
immune supplement that targets pathogenic bacteria and the toxins
they produce in the gastrointestinal (GI) tract.
Flavio Palumbo, Chief Commercial Officer, said,
“We continue to be excited by the strong sales results on
Travelan®. Immuron’s investment to drive awareness of the Travelan®
brand has seen continued strong sales results in Australia. We were
incredibly pleased to achieve record U.S. sales in FY24. We hope to
achieve strong North American growth in FY25 on the back of planned
increased brand investment and distribution.”
AustraliaSales of Travelan®
increased 236% to AUD $3.7 million for the full financial year to
June 2024 (FY24) compared to AUD $1.1 million for FY23. Sales of
Travelan® increased 209% to AUD $1.0 million for the June 2024
Quarter compared to AUD $0.3 million for the June 2023 Quarter
(excludes sales of Protectyn®).
Consistent with the increase in June 2024 quarter sales, the
Australian Bureau of Statistics reported short term resident
returns in April 2024 were 29% higher than April 20231.
USAWe achieved a new annual
record. The previous highest annual USA sales was AUD $1.0 million
in FY19.
Sales of Travelan® increased 74% to AUD $1.1
million for the full financial year to June 2024 (FY24) compared to
AUD $0.6 million for FY23.
Sales of Travelan® increased 546% to AUD $0.3
million in the June 2024 Quarter compared to AUD $0.05 million in
the June 2023 Quarter.
Immuron’s experience in the USA follows the
International Trade Administration Total U.S. citizen international
visitor departures from the United States in April 2024 being 8%
higher than in April 2023.2
-
www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release
-
www.trade.gov/us-international-air-travel-statistics-i-92-data
This release has been authorised by the directors of Immuron
Limited.
COMPANY
CONTACT:
Steven LydeamoreChief Executive OfficerPh: +61
(0)3 9824 5254info@immuron.com
About Travelan®Travelan® is an
orally administered passive immunotherapy that prophylactically
reduces the likelihood of contracting Travelers’ Diarrhea, a
digestive tract disorder that is commonly caused by pathogenic
bacteria and the toxins they produce. Travelan® is a highly
purified tabletized preparation of hyper immune bovine antibodies
and other factors, which when taken with meals bind to
diarrhea-causing bacteria and prevent colonization and the
pathology associated with Travelers’ Diarrhea. In Australia,
Travelan® is a listed medicine on the Australian Register for
Therapeutic Goods (AUST L 106709) and is indicated to reduce the
risk of Travelers’ Diarrhea, reduce the risk of minor
gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licensed natural health product (NPN 80046016) and
is indicated to reduce the risk of Travelers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract
protection.
About Travelers’
DiarrheaTravelers’ Diarrhea is a gastrointestinal
infection with symptoms that include loose, watery (and
occasionally bloody) stools, abdominal cramping, bloating, and
fever, Enteropathogenic bacteria are responsible for most cases,
with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a
significant proportion of cases. The more serious infections with
Salmonella spp. the bacillary dysentery organisms belonging to
Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with Travelers’ Diarrhea as they may be contracted
while travelling and initial symptoms are often
indistinguishable.
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
FORWARD-LOOKING STATEMENTS:This
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, each as amended. Such
statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any
other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock value.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; risks
relating to the results of research and development activities;
risks relating to the timing of starting and completing clinical
trials; uncertainties relating to preclinical and clinical testing;
our dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 7 2024 まで 8 2024
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 8 2023 まで 8 2024